Nonpeptide mimic of bradykinin with long-acting properties

Immunopharmacology

Volumn 45, Issue 1-3, 1999, Pages 185-190

  Aramori, Ichiro ^a   Zenkoh, Junko ^a   Morikawa, Noriyuki ^a   Asano, Masayuki ^b   Hatori, Chie ^b   Sawai, Hiroe ^b   Kayakiri, Hiroshi ^b   Satoh, Shigeki ^b   Inoue, Takayuki ^b   Abe, Yoshito ^b   Sawada, Yuki ^b   Mizutani, Tsuyoshi ^b   Inamura, Noriaki ^b   Iwami, Morita ^a   Nakahara, Kunio ^b   Kojo, Hitoshi ^a   Oku, Teruo ^b   Notsu, Yoshitada ^a  

^a Fujisawa Pharmaceutical 5 2 3 T   (Japan)

^b Exploratory Research Laboratories   (Japan)

Author keywords

Bradykinin receptors; FR190997; Nonpeptide agonist

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR AGONIST; INOSITOL PHOSPHATE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; INFLAMMATION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRADYKININ; CHO CELLS; CRICETINAE; GTP-BINDING PROTEINS; GUINEA PIGS; HUMANS; HYDROLYSIS; INJECTIONS, INTRAVENOUS; MOLECULAR MIMICRY; PEPTIDES; PROTEIN BINDING; QUINOLINES; RECEPTORS, BRADYKININ; RECEPTORS, CELL SURFACE;

EID: 0032734519     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00144-7     Document Type: Article

References (24)

1. 2 receptor antagonists: 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety. J. Med. Chem. 41:1998;4062-4079.
2. Aramori I., Nakanishi S. Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J. Biol. Chem. 267:1992;12468-12474.
3. Aramori I., Zenkoh J., Morikawa N., O'Donnell N., Asano M., Nakamura K., Iwami M., Kojo H., Notsu Y. Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol. Pharmacol. 51:1997;171-176.
4. 2 receptor. Mol. Pharmacol. 52:1997;16-20.
5. 2 receptor antagonist, FR173657. Br. J. Pharmacol. 120:1997;617-624.
6. 2 receptor antagonist, FR165649, and agonist, FR190997. Br. J. Pharmacol. 124:1998;441-446.
7. Berridge M.J., Dawson R.M.C., Downes C.P., Heslop J.P., Irvine R.F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem. J. 212:1983;473-482.
8. BjØrnstad-Østensen A., Berg T. The role of nitric oxide, adrenergic activation and kinin-degradation in blood pressure homeostasis following an acute kinin-induced hypotension. Br. J. Pharmacol. 113:1994;1567-1573.
9. De Lean A., Stadel J.M., Lefkowitz R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255:1980;7108-7117.
10. Dray A., Parkins M. Bradykinin and inflammatory pain. Trends Neurosci. 16:1993;99-104.
11. Feldberg W., Lewis G.P. The action of peptides on the adrenal medulla release of adrenaline by bradykinin and angiotensin. J. Physiol. 171:1964;98-108.
12. Gilman A.G. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56:1987;615-649.
13. Hess J.F., Borkowski J.A., Young G.S., Strader C.D., Ransom R.W. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun. 184:1992;260-268.
14. Hock F.J., Wirth K., Albus U., Linz W., Gerhards H.J., Wiemer G., Henke St., Breipohl G., Knig W., Knolle J., Schkens B.A. Hoe140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102:1991;769-773.
15. Levitzki A. From epinephrine to cyclic AMP. Science. 241:1988;800-806.
16. 2 bradykinin receptor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;7724-7728.
17. 1 bradykinin receptor. J. Biol. Chem. 269:1994;21583-21586.
18. Moore G.J., Smith J.R., Baylis B.W., Matsoukas J.M. Design and pharmacology of peptide mimetics. Advances in Pharmacology. 33:1995;91-141.
19. 1 ligands: susceptibility to receptor mutations. Mol. Pharmacol. 51:1997;301-311.
20. Proud D., Kaplan A.P. Kinin formation: mechanisms and role in inflammatory disorders. Annu. Rev. Immunol. 6:1988;49-83.
21. Regoli D., Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1980;1-46.
22. 2 receptor characterization. Trends Pharmacol. Sci. 11:1991;156-161.
23. 2 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A. 91:1994;4693-4697.
24. Wirth K., Hock F.J., Albus U., Linz W., Alpermann H.G., Anagnostopoulos H., Henke St., Breipohl G., Knöig W., Knolle J., Schökens B.A. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102:1991;774-777.